In this update:

… 18 MONTH CLINICAL STUDY RESULTS

… POTASSIUM CHANNEL STUDY: NEW INSIGHTS

… TRX2 KNOWLEDGEBASE

We are proud to present the results of our long-term 18 month clinical study. 59 participants (47 men and 12 women) entered the study and completed 18 months of therapy. The randomized, double-blind, placebo-controlled study was focused on evaluation of efficacy and safety of TRX2. The data show statistical significance at four major efficacy parameters:
Hair count (Mean number of hair in an area of 2×2 cm): +35.1% (after 9 months) and +49.2% (after 18 months)

Hair Thickness (Mean weight of hair – bundle of 30 strands): +22.5% (after 9 month) and +38.7% (after 18 months)

Terminal hair change (% change from vellus to non-vellus): +23.2% (after 9 month) and +36.4% (after 18 months)

Self-evaluation of satisfaction (score between 0-10 cm with 10 being the most satisfied): 7.8 ± 2.0 cm (after 9 month) and 8.6 ± 1.6 cm (after 18 months)

Please note that the % numbers given above are the means, i.e. contain the results of ALL participants within the test population. For instance, while the mean percentage increase in terms of hair count was 49.2% after 18 month, some individuals experienced a percentage increase of as much as 120%. Individual results varied depending on the participant’s type of hair loss and individual metabolism. Within the active treatment group 87% of participants recorded cessation of hair loss and a significant increase in the number of hair/hair thickness after 9 month of treatment. Those results are extremely encouraging for men and women suffering from hair loss. The efficacy of TRX2 combined with its safety and excellent tolerability may make this product a viable and attractive alternative to common treatments such as finasteride and minoxidil. Click here to read the the full research article online.

Read More »